1. Home
  2. SXI vs CRNX Comparison

SXI vs CRNX Comparison

Compare SXI & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standex International Corporation

SXI

Standex International Corporation

HOLD

Current Price

$305.34

Market Cap

3.5B

Sector

Industrials

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$83.89

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXI
CRNX
Founded
1955
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.9B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
SXI
CRNX
Price
$305.34
$83.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$289.67
$76.75
AVG Volume (30 Days)
230.9K
6.0M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
0.54%
N/A
EPS Growth
N/A
N/A
EPS
6.98
N/A
Revenue
$604,535,000.00
$1,039,000.00
Revenue This Year
$14.87
$720.10
Revenue Next Year
$6.07
$184.67
P/E Ratio
$43.97
N/A
Revenue Growth
N/A
N/A
52 Week Low
$158.63
$25.83
52 Week High
$363.89
$84.00

Technical Indicators

Market Signals
Indicator
SXI
CRNX
Relative Strength Index (RSI) 47.87 92.96
Support Level $300.49 $40.74
Resistance Level $363.89 N/A
Average True Range (ATR) 12.63 0.66
MACD -3.92 1.48
Stochastic Oscillator 18.15 99.75

Price Performance

Historical Comparison
SXI
CRNX

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: